کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1426366 | 986808 | 2009 | 6 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Development of a sustained-release recombinant human growth hormone formulation Development of a sustained-release recombinant human growth hormone formulation](/preview/png/1426366.png)
Recombinant human growth hormone (rhGH) therapy for short stature must be administered as a daily injection because of its poor bioavailability and short half-life. In the present study, a sustained-release formulation of rhGH (SR-rhGH), DA-3003, was prepared using double emulsion solvent evaporation with poly(D,L-lactide-co-glycolide) (PLGA), zinc oxide and hydroxypropyl-β-cyclodextrin (HPCD) as the release modulator, stabilizer, and aggregation–prevention agent, respectively. After a single administration of DA-3003, the elevated concentration of rhGH in plasma was sustained for 14 days in rats and 28 days in monkeys. The plasma concentration of insulin-like growth factor-1 (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3), which are pharmacodynamic markers of rhGH administration, increased and remained elevated for approximately 28 days in monkeys. Monkeys administered DA-3003 did not develop antibodies to hGH, indicating safety of the SR-rhGH formulation comparable to that observed with daily rhGH injections (Growtropin® II). There were no significant differences in efficacy between Growtropin® II (daily dose of 5 μg/animal for 14 days) and DA-3003 (weekly dose of 35 μg/animal for 14 days with a dosing interval of a week) in hypophysectomized rats, as assessed by changes in body weight and the width of the tibial growth plate. These results show that a sustained-release rhGH formulation, DA-3003, has the potential to be used safely and efficaciously in a weekly dosing regimen.
Figure optionsDownload as PowerPoint slide
Journal: Journal of Controlled Release - Volume 137, Issue 2, 20 July 2009, Pages 160–165